Dyne Therapeutics Stock (NASDAQ:DYN)

Forecast Ownership Financials Chart

Previous Close

$25.63

52W Range

$8.88 - $26.26

50D Avg

$20.55

200D Avg

$18.94

Market Cap

$4.28B

Avg Vol (3M)

$2.08M

Beta

1.06

Div Yield

DYN Company Profile

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

263

IPO Date

Sep 17, 2020

Website

DYN Performance

DYN Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-468.18M	$-343.89M	$-242.16M
Net Income	$-446.21M	$-317.42M	$-235.94M
EBITDA	$-468.18M	$-315.18M	$-233.48M
Basic EPS	$-3.47	$-3.37	$-3.95
Diluted EPS	$-3.47	$-3.37	$-3.95

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 17Aug 04, 17 | 5:00 PM

Q1 17May 06, 17 | 5:00 PM

Q4 16Feb 24, 17 | 5:00 PM

Peer Comparison

Ticker	Company
TLX	Telix Pharmaceuticals Limited
AAPG	Ascentage Pharma Group International
MIRM	Mirum Pharmaceuticals, Inc.
RARE	Ultragenyx Pharmaceutical Inc.
CELC	Celcuity Inc.
CGON	CG Oncology Inc.
XENE	Xenon Pharmaceuticals Inc.
APGE	Apogee Therapeutics, Inc.